Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01208233 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT01208233 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 181 participants.
The verdict
NCT01208233, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy of PF-03049423, relative to placebo, in subjects with ischemic stroke following 90 days of therapy. The study will also explore the relationship between PF-03049423 concentration and blood pressure.
Interventions
- OTHER Placebo
- DRUG PF-03049423
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01208233
The ClinicalTrials.gov registry entry for NCT01208233 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01208233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01208233 about?
NCT01208233 is a clinical study titled "Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke". The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy of PF-03049423, relative to placebo, in subjects with ischemic stroke following 90 days of therapy. T...
What is the current status of trial NCT01208233?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2010-12. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01208233?
The interventions under investigation include: Placebo (OTHER), PF-03049423 (DRUG).
Who is sponsoring clinical trial NCT01208233?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.